Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma
Open Access
- 31 July 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (15), 3801-3809
- https://doi.org/10.1158/1078-0432.ccr-15-2825
Abstract
Purpose:The prognostic impact of total metabolic tumor volume (TMTV) measured on pretreatment 18F-FDG PET/CT and its added value to molecular characteristics was investigated in patients with diffuse large B-cell lymphoma (DLBCL). Experimental Design:For 81 newly diagnosed DLBCL patients, treated with Rituximab and CHOP/CHOP-like regimen, TMTV was computed using the 41% SUVmax thresholding method. According to the gene expression profile, determined using DASL (cDNA-mediated Annealing, Selection, Ligation and extension) technology, a subset of 57 patients was classified in GCB or ABC subtypes and MYC or BCL2 overexpressed. Results:Median follow-up was 64 months. 5y-PFS and OS were 60% and 63% in the whole population. Median pre-therapy TMTV was 320 cm3 (25th-75th percentiles 106-668 cm3). With a 300cm3cut off, patients with high TMTV (n=43) had a 5 y-PFS and OS of 43% and 46% compared with 76% and 78% for patients with a low TMTV (p=0.0023, p=0.0047). ABC status, MYC or BCL2 overexpression and both overexpression ("dual expressor", DE) were significantly associated with a worse PFS and OS. TMTV combined with molecular data allowed a significant better risk sub-stratification of ABC/GCB patients, on PFS and OS. High TMTV individualized in molecular low risk patients a group with a poor outcome (MYC, PFS=51%, OS=55% BCL2, PFS=49%, OS=49% or DE PFS=50%, OS=50%) and a group with a good outcome (MYC, PFS=93%, OS=93% BCL2, PFS=86%, OS=86% or DE PFS=81%, OS=81%). Conclusions:The combination of molecular and imaging characteristics at diagnosis could lead to a more accurate selection of patients, in order to increase tailor therapy.Keywords
Other Versions
This publication has 40 references indexed in Scilit:
- MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapyHaematologica, 2013
- Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphomaCancer, 2012
- Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvementAnnals of Hematology, 2011
- Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphomaLeukemia & Lymphoma, 2011
- Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded TissuesClinical Cancer Research, 2011
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010
- FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2009
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Response Assessment of Aggressive Non-Hodgkin’s Lymphoma by Integrated International Workshop Criteria and Fluorine-18–Fluorodeoxyglucose Positron Emission TomographyJournal of Clinical Oncology, 2005
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000